Navigation Links
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Date:12/9/2009

lopment and expedite the review of drugs that treat serious diseases and fill an unmet medical need based on the need for safer non-invasive tests to diagnose pancreatic disorders. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could directly benefit by the addition of RG1068.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statem
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
2. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
3. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
4. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
5. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
8. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
9. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
10. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
11. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 ... diversifies revenue base with highly profitable specialty products ... , Near-term growth potential with 11 product applications ... Paragraph IV certifications  , Provides medium and ... in development, including eight controlled substances , ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has ... (London, UK - November 19-20, 2015)" conference to ... will cover industry case studies, regulatory updates, latest therapies ... Dr Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar ...
(Date:9/2/2015)... YORK , Sept. 2, 2015  Seeger Weiss ... implant bellwether trial will commence October 13, 2015. ... using the 510K fast-track approval program, Zimmer NexGen knee ... program only requires that companies provide evidence that the ... product in order to gain permissions. ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Telehealth represents ... Well Corp., contracted to handle the telehealth services of more than 12 Blues plan ... and Blue Shield Plans takes a look this growing trend, interviewing executives at Capital ...
(Date:9/2/2015)... ... 02, 2015 , ... In “Failure Lab: Weight Loss Surgery was Never the ... writer Akela Stanfield detailed her lifelong struggle with obesity that eventually led her to ... seen herself as someone who would lose weight through sheer self-control, the dawning realization ...
(Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... ... Internet of Things, announces its latest addition to its screen mirroring and extending ... award-winning Splashtop Extended Wireless Display, which operates in local WIFI setting, the new ...
(Date:9/2/2015)... ... September 02, 2015 , ... Good health and a ... Blue Shield of New Jersey (Horizon BCBSNJ) donated $11,000 to the New Jersey Golf ... the foundation at the start of The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... clinic combining both naturopathic and allopathic medicine, opens its second location this week ... clinic features roughly 1000 square feet of lounge space for patients to relax ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4
... ... continues to challenge scientists. There is growing evidence that increases in protease ... team of scientists at the University of Alabama measured a common protease ... with healthy volunteers. Previous studies have shown increases in MMP-9 in CF ...
... erlotinib for people with non-small-cell form of disease ... with non-small-cell lung cancer, treatment with the drug erlotinib ... a new study suggests. , Non-small-cell lung cancer ... About half the time, people have advanced disease when ...
... ... Systems, Inc. announces the NanaWall SL60 is featured in the winning ... by the USGBC for interior designers to showcase the best hospitality ... The NanaWall connects the hotel suite to an outdoor lounge expanding ...
... Years ... finally pay off for victims of severe psychological harassment who are lobbying for the right ... documentary, NoJobIsWorthThis.com , ... 20, 2010 -- New York’s State Senate recently passed landmark legislation that steps up the ...
... ... The cost of healthcare is out of control! Brandi Funk is a ... healthcare and research experience to her quest to aid consumers. “It ... Funk. In her new, informative book, "Cut Your Health Care Costs Now!" ...
... A ... relationship is required, not just discipline. , ... (PRWEB) May 20, 2010 -- There’s a dangerous parenting trend occurring that does ... or not to spank, etc.) with little to no attention on a valuing parent/child ...
Cached Medicine News:Health News:News from Molecular Medicine 2Health News:Post-Chemo Treatment May Boost Lung Cancer Survival 2Health News:NanaWall Featured in Award-winning Green Hotel Suite 2Health News:NanaWall Featured in Award-winning Green Hotel Suite 3Health News:There Oughta Be A Law: NY Poised to Lead U.S. in Fight to Stop Workplace Bullying 2Health News:New Healthcare Book Helps Families Navigate Rising Healthcare Costs and Decreasing Coverage 2Health News:Celebrate Mental Health Month with Your Child; Make Sure a Valuing Relationship is in Place 2
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... The NOW Hepatitis B test is a ... diagnosis of a Hepatitis B infection. This simple, ... for accurate treatment and improved patient outcomes. , ... is an in vitro immunodiagnostic test for the ...
... is the newest technology available in acrylic ... combines exceptional material and design properties to ... Biostability , Unique foldable hydrophobic acrylic material ... be biostable , High index of ...
Single Use Loading Units with Titanium Staples for use with Powered MULTIFIRE ENDO GIA™ 60 (15 mm Single Use Stapler with Titanium Staples)....
Medicine Products: